- Home
- STK vs MGTX Comparison
STK vs MGTX Comparison
Compare STK & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STK | MGTX |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 921.0M | 1.0B |
| IPO Year | 2009 | 2018 |
Fundamental Metrics
Financial Performance| Metric | STK | MGTX |
|---|---|---|
| Price | $52.77 | $9.22 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $27.75 |
| AVG Volume (30 Days) | 40.6K | ★ 819.2K |
| Earning Date | 01-01-0001 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.02 |
| EPS | N/A | ★ 1.30 |
| Revenue | N/A | ★ $81,391,000.00 |
| Revenue This Year | N/A | $314.19 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $7.09 |
| Revenue Growth | N/A | ★ 144.57 |
| 52 Week Low | $32.50 | $6.62 |
| 52 Week High | $58.46 | $15.35 |
Technical Indicators
Market Signals| Indicator | STK | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.89 | 31.90 |
| Support Level | $50.58 | $8.84 |
| Resistance Level | $53.39 | $10.06 |
| Average True Range (ATR) | 1.17 | 0.52 |
| MACD | -0.30 | 0.01 |
| Stochastic Oscillator | 29.25 | 6.12 |
Price Performance
Historical ComparisonAbout STK Columbia Seligman Premium Technology Growth Fund Inc
Columbia Seligman Premium Technology Growth Fund Inc is a closed-end management investment company. Its investment objective is to seek growth of capital and current income. The fund invests in various sectors such as consumer discretionary, industrials, information technology and telecommunication services.
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.